title: [Comparative antihypertensive action of 20 mg delayed-action nifedipine with either 25 or 50 mg atenolol. A study on the treatment of patients with mild to moderately severe arterial hypertension].
abstract: In the present double-blind, randomized, placebo-controlled study 36 untreated patients (57.8 +/- 8.4 years) with mild to moderate hypertension were included. After a 14 days' placebo period they were treated with a combination of 20 mg retarded nifedipine and 25 or 50 mg atenolol for six weeks each. Group A started with 25 mg, group B with 50 mg atenolol. Casual sitting blood pressure was measured automatically every second week, routine laboratory parameters and side effects were evaluated at the end of placebo and the verum periods. The blood pressure of the two groups was comparable during placebo and was reduced by 31.6/14.7 mmHg in group A or 29.9/15.8 mmHg in group B (p < 0.001 vs. placebo) after six weeks. In the second treatment period with verum, blood pressure was not further reduced. Both combinations were equally efficient also in the female and the elder subgroups (> 60 years) who were characterized by higher systolic blood pressure. The response rates were 83% and 86% for the combination with 25 and 50 mg atenolol respectively. Heart rate was significantly reduced in all groups during 50 mg atenolol. Laboratory parameters were not altered by treatment. Frequency and severeness of side effects were equal in both groups. It is concluded that in patients with mild to moderate uncomplicated hypertension the combination of 20 mg retarded nifedipine with 25 mg atenolol is equally efficient to the combination with 50 mg atenolol.
authors.affiliation: Medizinische Poliklinik, Universität Bonn.
authors.forename: K
authors.initials: K
authors.lastname: Kraft
authors.forename: S
authors.initials: S
authors.lastname: Schiessl
authors.forename: H
authors.initials: H
authors.lastname: Vetter
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001262:Atenolol / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage*
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D001262:Atenolol; D009543:Nifedipine